Your browser doesn't support javascript.
loading
[Systemic safety following intravitreal injections of anti-VEGF]. / Tolérance systémique des injections intravitréennes d'anti-VEGF.
Baillif, S; Levy, B; Girmens, J-F; Dumas, S; Tadayoni, R.
Affiliation
  • Baillif S; Département d'ophtalmologie, hôpital Pasteur, 30, voie Romaine, 06000 Nice cedex 1, France. Electronic address: baillif.s@chu-nice.fr.
  • Levy B; Institut des vaisseaux et du sang, département physiologie clinique, Inserm U970, hôpital Lariboisière, 75010 Paris, France.
  • Girmens JF; Département d'ophtalmologie du Professeur-Sahel-&-CIC, hôpital Quinze-Vingt, 75012 Paris, France.
  • Dumas S; Clinique Nord-Vision, 59800 Lille, France.
  • Tadayoni R; Département d'ophtalmologie, hôpitaux de Paris, hôpital Lariboisière, 75010 Paris, France.
J Fr Ophtalmol ; 41(3): 271-276, 2018 Mar.
Article in Fr | MEDLINE | ID: mdl-29567019
The goal of this manuscript is to assess data suggesting that intravitreal injection of anti-vascular endothelial growth factors (anti-VEGFs) could result in systemic adverse events (AEs). The class-specific systemic AEs should be similar to those encountered in cancer trials. The most frequent AE observed in oncology, hypertension and proteinuria, should thus be the most common expected in ophthalmology, but their severity should be lower because of the much lower doses of anti-VEGFs administered intravitreally. Such AEs have not been frequently reported in ophthalmology trials. In addition, pharmacokinetic and pharmacodynamic data describing systemic diffusion of anti-VEGFs should be interpreted with caution because of significant inconsistencies reported. Thus, safety data reported in ophthalmology trials and pharmacokinetic/pharmacodynamic data provide robust evidence that systemic events after intravitreal injection are very unlikely. Additional studies are needed to explore this issue further, as much remains to be understood about local and systemic side effects of anti-VEGFs.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiogenesis Inhibitors / Vascular Endothelial Growth Factor A Limits: Humans Language: Fr Journal: J Fr Ophtalmol Year: 2018 Document type: Article Country of publication: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiogenesis Inhibitors / Vascular Endothelial Growth Factor A Limits: Humans Language: Fr Journal: J Fr Ophtalmol Year: 2018 Document type: Article Country of publication: France